Close

News

Mylan Launches Generic Version of Wellbutrin XL(R) Tablets

Mylan Pharmaceuticals Inc. has launched Bupropion Hydrochloride Extended-release Tablets USP, (XL), 150 mg and 300 mg (Once-Daily), the generic version of GlaxoSmithKline's antidepressant Wellbutrin XL(R). Bupropion Hydrochloride Extended-release Tablets had U.S. sales of approximately $752 million...

Emisphere Reports Positive Clinical Results for Its Oral Drug Delivery Technology

Emisphere Technologies, Inc. announced that a clinical study found that the company's proprietary oral SNAC (Sodium N- Caprylate ("SNAC") additive, in combination with two digestive hormones, was successful in reducing food intake and increasing satiety in healthy male subjects....

Movianto opens second warehouse in Orléans

Movianto France, the logistics and distribution company specialising in pharmaceuticals and healthcare has expanded its presence in France by opening a second warehouse in Orléans. Alongside the present warehouse, near the airport Charles-de-Gaulle in Paris, which...

Ironwood and Forest Announce Positive Linaclotide Results from Phase 3

Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc.announced positive top-line results from the first of two Phase 3 clinical trials assessing the efficacy and safety of the investigational drug, linaclotide, in patients with irritable bowel syndrome with constipation (IBS-C). Analyses...

Bristol-Myers Squibb Begins Tender Offer to Acquire ZymoGenetics, Inc.

Bristol-Myers Squibb Company is commencing , through its wholly owned subsidiary Zeus Acquisition Corporation, a cash tender offer to purchase all outstanding shares of common stock of ZymoGenetics, Inc. (NASDAQ: ZGEN). Bristol-Myers Squibb announced on Tuesday, September 7, 2010...

Dr Reddy’s launches darbepoetin alfa in India – World’s first generic darbepoetin alfa and the only one in India

  Dr. Reddy’s Laboratories Ltd. announced the launch of Cresp®’- the first generic darbepoetin alfa in the world, and the only darbepoetin alfa in India. Cresp® has been approved in India for the treatment of anemia due to chronic...

Glenmark announces the Discovery of a novel chemical entity ‘GRC 17536’, a potential first-in-class molecule globally

Glenmark Pharmaceuticals announced the discovery of a Novel Chemical Entity(NCE) 'GRC 17536'. The new NCE program is targeting TRPA1 recept or antagonists for pain and respiratory disorders. TRPA1 belongs to Transient Receptor Potential(TRP) family of ion channels, which have...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read